Board of Directors

Seng Chin Mah is an independent healthcare advisor with over 30 years’ experience in the Pharma and Biotech industry, both in public and privately held companies. Dr. Mah is Chairman of BioVersys AG (a SIX-listed company) and is also a member of the boards of OSR Holdings Inc (a NASDAQ-listed company), Vaccentis AG and Akceso Advisors AG. He was formerly the Chief Executive Officer of the Canyon Pharmaceuticals Group AG where he transacted a corporate inversion of a US registered company to Switzerland. Prior to Canyon Pharmaceuticals, he was the Head of Development of the Integration Office during the integration of Chiron into Novartis and has previously held positions including the Global Head of Clinical Safety and Epidemiology, interim Global Head of Drug Regulatory Affairs and Head of Drug Regulatory Affairs Europe. He also had oversight responsibility for Clinical Quality Assurance across the Novartis group. Dr. Mah was also a member of the Novartis Corporate Executive Group and a member of the board of directors for Novartis Europharm Ltd in the UK. During his tenure with Novartis and Ciba, he has driven transformational programs, managed large global organizations, and achieved significant business results such as the numerous global registrations of major products. Dr. Mah has worked extensively on both development projects and marketed products. He has held numerous research and academia positions. Dr. Mah is an award-winning CEO of a biotech - The Frost & Sullivan 2011 Product Differentiation Excellence Award in Parenteral Anticoagulants recognized Canyon Pharmaceuticals Group AG for the development and launch of Iprivask® (desirudin for injection). He subsequently effected an asset transaction of the product. He possesses deep knowledge in strategic decision-making within the Pharma and Biotech industry, late-stage clinical development, regulatory and business experience as well as people development skills.

Marc is Chief Executive Officer and co-founder of BioVersys with over 10 years of experience in the biotech industry, having launched a university spin-off in the field of antimicrobial resistance and growing it into a multi-asset clinical stage company. Some of these assets will address significant unmet medical needs in infectious conditions such as tuberculosis and hospital acquired Acinetobacter infections. Marc has raised over $70 mio in equity financing and secured over $30 mio in non-dilutive funding. He has also established several important partnerships with a Big Pharma and other development organizations. Multi-award-winning Biotech CEO, having received amongst others the Swiss Technology Award 2011, Venture Kick 2009 and Venture Leaders 2008 and 2017 awards for his work in founding and advancing BioVersys. He is also President of the Board of the BEAM Alliance, a European association representing over 70 European and international SMEs active in antimicrobial research and development and Board member of AMR Industry Alliance. Marc is a young thought leader in the field of antimicrobial research and development. He is passionate about next generation antimicrobial therapies and leads a highly motivated team striving to bring life-saving antimicrobial therapies to patients in need. He is also co-author on several high ranked scientific publications and patents in the field.

Marina von Schönau is Chairwoman of Almacos AG and investor representative of a family office where she takes care of the private equity portfolio. Almacos AG is a management consultancy that is active in companies in the private equity space in real estate, healthcare including digital health, recycling, food appliances and financial services, with an emphasis on helping management retain entrepreneurial values. She holds various board positions in privately held companies, including dacadoo AG as well as foundations such as the Coralma Stiftung AG. Over the last decade, Ms. von Schönau has been focused on advising venture opportunities, growth scenarios and complex restructurings especially within biotechnology, digital healthcare and recycling. As an investor, she has particular interests in the healthcare sector especially nutrition and in the recycling industry. In her prior career, Ms. von Schönau has worked in senior positions at different multi-national companies in the pharmaceutical sector including Janssen Cilag AG and Bayer (Schweiz) AG where she gained in depth knowledge of marketing, product launches and leadership. She has worked on products in the central nervous system (CNS) therapeutic area and women’s health. She was also a member of an international marketing frame group for a new product where she drove e-business ideas. Under her leadership, the CNS therapeutic area played a leading role in the initiation and expansion of the company's e-business platforms. Ms. von Schönau has a strong interest in the tremendous business potential and culture of Asia, in particular the fast pace of innovation in the fields of nutrition and hedge fund portfolios.

Simona Skerjanec is a senior advisor with nearly three decades of broad international and USA experience in the pharmaceutical industry. Ms. Skerjanec was previously the Senior Vice President and Global Neuroscience Head at Hoffmann-La Roche in Switzerland and led the business and global strategy for Roche’s portfolio of neurological and rare diseases, including Ocrevus® for the treatment of multiple sclerosis and a novel monoclonal antibody for the treatment of Alzheimer’s disease. During her nine-year tenure at Roche, she also served as General Manager of Roche Portugal. Prior to joining Roche, Ms. Skerjanec was Senior Vice President and Cardiovascular franchise head at The Medicines Company where she held various roles of increasing responsibilities in development and commercialization. She also held positions at Eli Lilly, Pfizer, and Johnson & Johnson. She has led multiple research and development efforts that have resulted in regulatory approvals and launches of commercial therapies in therapeutic areas including neurology and cardiology in the U.S. and other countries. Ms. Skerjanec currently serves on the boards of public biotechnology companies Atrium Therapeutics and Immunic Therapeutics as well as on the board of a Canadian private technology/AI startup PerceivAI. She was a board member of Avidity Biosciences until its successful exit in 2026.